pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US is a pharma organization headquartered in basking ridge, USA. Primary therapeutic focus areas include Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical conditio
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
Quick answer
Daiichi Sankyo US is a pharma organization headquartered in basking ridge, USA. Primary therapeutic focus areas include Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical condition., Non-small Cell Lung Cancer, Ovarian Cancer. NovaPharmaNews links 58 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (22), phase 2 (19), phase 1 (17).
Company snapshot
Daiichi Sankyo US maintains 58 tracked programs across Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical condition., Non-small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumors, Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC), HER2-expressing endometrial cancer (IHC 3+/2+), Locally Advanced or Metastatic Urothelial Car
- 58 active pipeline program(s) linked via ClinicalTrials.gov.
- 58 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Daiichi Sankyo US. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
- deal
Analysis of BMS-Hengrui's $15B Deal and Its Implications
- approval
Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough
- approval
Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More
- approval
FDA Approval for Datroway: Implications for Breast Cancer Treatment
- approval
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
- deal
Merck's ADC Success: Insights from Global Trial Results
- approval
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
- approval
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
- approval
EMA backs datopotamab deruxtecan for advanced lung cancer
- approval
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
- approval
PMDA approves ENHERTU for HER2-low breast cancer in Japan
Recent coverage
PMDA approves ENHERTU for HER2-low breast cancer in Japan
PMDA approved ENHERTU for unresectable or metastatic HER2-low breast cancer in Japan, marking a new regulatory catalyst for Daiichi Sankyo and AstraZeneca. The decision expands the drug’s labeled use in a major market and adds another milestone for investors tracking ENHERTU.
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
EMA backs datopotamab deruxtecan for advanced lung cancer
EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Daiichi Sankyo US.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Daiichi Sankyo US.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Daiichi Sankyo US?
-
Is Daiichi Sankyo US publicly traded?
-
What drugs does Daiichi Sankyo US develop or market?
-
What are the latest developments for Daiichi Sankyo US?
-
What therapeutic areas does Daiichi Sankyo US focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Daiichi Sankyo US maintains 58 tracked programs across Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical condition., Non-small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumors, Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC), HER2-expressing endometrial cancer (IHC 3+/2+), Locally Advanced or Metastatic Urothelial Carcinoma, Metastatic Solid Tumor, Advanced Solid Tumor, High-Risk HER2-Positive Breast Cancer. Momentum score: 35/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: basking ridge USA. Ticker: ECC3BD2.
Pipeline programs
Trastuzumab Deruxtecan — phase phase_3, status active. Indication: Ovarian Cancer. Next milestone: not disclosed (TBD).
DS6000-109 — phase phase_3, status active. Indication: Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer. Next milestone: not disclosed (TBD).
DS8201-A-U305 — phase phase_3, status active. Indication: High-Risk HER2-Positive Breast Cancer. Next milestone: not disclosed (TBD).
Trastuzumab Deruxtecan — phase phase_3, status active. Indication: Non-small Cell Lung Cancer. Next milestone: not disclosed (TBD).
U31402-A-U301 — phase phase_3, status active. Indication: Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC). Next milestone: not disclosed (TBD).
CS-3150 — phase phase_3, status completed. Indication: Hypertension. Next milestone: not disclosed (TBD).
DS8201-772 — phase phase_3, status active. Indication: Ovarian Cancer. Next milestone: not disclosed (TBD).
DS8201-A-U302 — phase phase_3, status active. Indication: Metastatic breast cancer. Next milestone: not disclosed (TBD).
Edoxaban — phase phase_3, status completed. Indication: Cardiac Disease. Next milestone: not disclosed (TBD).
Trastuzumab Deruxtecan — phase phase_3, status active. Indication: Gastric Cancer. Next milestone: not disclosed (TBD).
DS8201-724 — phase phase_3, status active. Indication: Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer. Next milestone: not disclosed (TBD).
Datopotamab deruxtecan, DOCETAXEL — phase phase_3, status active. Indication: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: PMDA approves ENHERTU for HER2-low breast cancer in Japan (2026-06-10).
Nova coverage: EMA backs datopotamab deruxtecan, but lung cancer access remains unclear (2026-06-07).
Nova coverage: EMA backs datopotamab deruxtecan for advanced lung cancer (2026-06-07).
Nova coverage: AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint (2026-06-07).
Nova coverage: AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma (2026-06-04).
Nova coverage: Merck's ADC Success: Insights from Global Trial Results (2026-06-01).
Nova coverage: ESMO 2025 Preview: Astra and Daiichi vs. Gilead (2026-05-30).
Nova coverage: AstraZeneca and Daiichi Secure FDA Approval for Datroway in TNBC (2026-05-23).
Registry facts
Registry profile: founded unknown; employees 4386; market cap n/a; revenue n/a; LEI 529900KWG23WIJDPKP09; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.833.
Catalyst calendar
Catalyst: Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes — type approval, date 2026-05-17.
Catalyst: Analysis of BMS-Hengrui's $15B Deal and Its Implications — type deal, date 2026-05-18.
Catalyst: Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough — type approval, date 2026-05-19.
Catalyst: Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More — type approval, date 2026-05-19.
Catalyst: FDA Approval for Datroway: Implications for Breast Cancer Treatment — type approval, date 2026-05-23.
Catalyst: ESMO 2025 Preview: Astra and Daiichi vs. Gilead — type approval, date 2026-05-30.
Catalyst: Merck's ADC Success: Insights from Global Trial Results — type deal, date 2026-06-01.
Catalyst: AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma — type approval, date 2026-06-04.
Catalyst: AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint — type approval, date 2026-06-07.
Catalyst: EMA backs datopotamab deruxtecan for advanced lung cancer — type approval, date 2026-06-07.
Competitive peers
Peer: BEONE MEDICINES AUS (overlap score 40.0).
Peer: Arcus Biosciences (overlap score 30.6).
Peer: Eikon Therapeutics (overlap score 23.0).
Peer: BeiGene (overlap score 22.8).
Peer: Medicenna Therapeutics (overlap score 20.6).
Peer: Multitude Therapeutics (overlap score 20.4).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.